Key result
Endovascular interventions for intermediate-risk pulmonary embolism have surged in use despite lacking robust randomized trial evidence for mortality or symptom burden.
Why the study?
Does endovascular therapy improve short- or long-term patient-centred outcomes compared to anticoagulation alone in patients with intermediate-high risk pulmonary embolism?
Does endovascular therapy improve short- or long-term patient-centred outcomes compared to anticoagulation alone in patients with intermediate-high risk pulmonary embolism?
Answers are grounded in this paper and cite their sources.
This editorial highlights the rapid growth of endovascular interventions for intermediate-risk pulmonary embolism despite a lack of robust, patient-centered RCT evidence, advocating for selective restraint and adherence to guideline-recommended anticoagulation until ongoing pivotal trials (HI-PEITHO, PEERLESS II, PE-TRACT) are completed.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Guerci et al. (2025) conducted an editorial in Intermediate-risk pulmonary embolism. Endovascular interventions (percutaneous thrombectomy and catheter-directed thrombolysis) vs. Systemic anticoagulation alone was evaluated. Endovascular interventions for intermediate-risk pulmonary embolism have surged in use despite lacking robust randomized trial evidence for mortality or symptom burden.
Synapse has enriched 10 related papers. Consider them for comparative context: